Sophie Mukadam - 01 Jan 2025 Form 3 Insider Report for Benitec Biopharma Inc. (BNTC)

Role
Chief Operating Officer
Signature
/s/ Louis Rambo, Attorney-in-Fact for Sophie Mukadam
Issuer symbol
BNTC
Transactions as of
01 Jan 2025
Net transactions value
$0
Form type
3
Filing time
03 Jan 2025, 17:39:57 UTC
Next filing
20 Nov 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding BNTC Common Stock, par value $0.0001 per share 6,016 01 Jan 2025 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BNTC Options (right to buy) 01 Jan 2025 Common Stock 141 $50.66 Direct F1
holding BNTC Options (right to buy) 01 Jan 2025 Common Stock 1,034 $79.90 Direct F2
holding BNTC Options (right to buy) 01 Jan 2025 Common Stock 5,294 $3.91 Direct F3
holding BNTC Options (right to buy) 01 Jan 2025 Common Stock 100,000 $5.21 Direct F4
holding BNTC Options (right to buy) 01 Jan 2025 Common Stock 300,000 $12.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options vested in three substantially equal installments on December 9, 2021, December 9, 2022 and December 9, 2023.
F2 The stock options vested in three substantially equal installments on June 14, 2022, June 14, 2023, and June 14, 2024.
F3 Stock options for 1,764 shares vested on June 13, 2024. The remainder of the stock options will vest in two substantially equal installments on June 13, 2025 and June 13, 2026.
F4 The stock options will vest in three substantially equal installments on March 6, 2025, March 6, 2026, and March 6, 2027.
F5 The stock options will vest in sixteen substantially equal quarterly installments commencing on March 31, 2025.

Remarks:

Exhibit 24 - Power of Attorney